Prognostic value of an integrated immune-inflammatory phenotype in surgically treated cervical cancer: survival modeling and immunohistochemical validation - Summary - MDSpire
Advertisement
Prognostic value of an integrated immune-inflammatory phenotype in surgically treated cervical cancer: survival modeling and immunohistochemical validation
To investigate whether an integrated immune-inflammatory phenotype combining stromal tumor-infiltrating lymphocytes (TILs) and the systemic immune-inflammation index (SII) could improve recurrence-free survival (RFS) stratification after surgery in cervical cancer patients, thereby enhancing prognostic accuracy beyond conventional factors.
Approach:
Key Findings:
119 patients experienced an RFS event during follow-up, highlighting the clinical relevance of the findings.
Significant RFS differences were observed according to TIL category, SII category, and integrated phenotype, suggesting potential for tailored treatment strategies.
FIGO IIIC disease, positive margin status, and poor integrated phenotype were independently associated with worse RFS, indicating critical factors for risk assessment.
LASSO-Cox achieved the highest C-index (0.782) and best discrimination at 24 and 36 months, supporting its use in clinical decision-making.
Immunohistochemical validation indicated that the favorable phenotype was characterized by higher CD8+ cell density and lower CD163+ cell density, reinforcing the importance of immune profiling.
Interpretation:
An integrated immune-inflammatory phenotype combining stromal TILs and SII was independently associated with postoperative recurrence risk in cervical cancer and corresponded to distinct tissue immune states.
Limitations:
The study is retrospective and may be subject to selection bias, and potential confounding factors were not fully accounted for.
Findings may not be generalizable to all cervical cancer populations due to the specific cohort studied.
Conclusion:
The integrated immune-inflammatory phenotype may provide a practical framework for recurrence risk stratification, while LASSO-Cox and RSF offer complementary prognostic perspectives, potentially guiding personalized treatment approaches.